Selective Serotonin Reuptake Inhibitor
Fluoxetine for Anxiety and Depression
This trial uses fMRI to study brain regions engaged in processing motivationally salient stimuli in children, adolescents, and adults with mood and anxiety disorders, in order to better understand how these disorders develop and how they can be treated.
Device Validation Using Blood Samples for Thrombotic Thrombocytopenic Purpura
This trial is for a new device that needs to be validated with known samples. 3 ml of blood is needed from people diagnosed with hTTP. You will be compensated for your time and resources.
Blood Collection Device Validation for Patients Taking Blood Thinners
This trial is to help a manufacturer qualify their line of blood collection tubes with the FDA, which will help increase the supply of blood collection tubes. Participants on anticoagulants such as Pradaxa®, Xarelto®, Eliquis®, Coumadin®, Normiflo ®, Fragmin®, or Lovenox® are compensated for their time and resources (up to $200 for a 3.5 tablespoon blood draw).
Blood Collection Device Validation for Patients on Blood Thinners
This trial is for a medical device manufacturer to qualify their line of blood collection tubes with the FDA. Participants who are currently on anticoagulants will be compensated for their time and resources.
Cell Therapy
Islet Cell Transplant for Type 1 Diabetes
This trial is testing if it's safe to transplant human islet cells to help control blood sugar in type 1 diabetes patients who have trouble controlling it. Early observations will also be made about if this treatment can help with hypoglycemia.
Popular Filters
Trials for Ductal Carcinoma Patients
Alkylating agents
Chemotherapy +/− Bevacizumab for Breast Cancer
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Trials for Adenocarcinoma Patients
Hormone Therapy
Androgen Ablation Therapy + Chemotherapy for Prostate Cancer
This trial is studying androgen-ablation therapy and docetaxel to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Phase 3 Trials
Corticosteroid
Budesonide for Chronic Obstructive Pulmonary Disease
This trial tests if a triple medication inhaler can improve heart and lung health in high-risk COPD patients better than a dual medication inhaler. Using a single inhaler with three medications has been shown to improve lung function and reduce flare-ups in COPD patients compared to using two medications, but it may increase the risk of pneumonia.
Hormone Therapy
Androgen Ablation Therapy + Chemotherapy for Prostate Cancer
This trial is studying androgen-ablation therapy and docetaxel to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Alkylating agents
Chemotherapy +/− Bevacizumab for Breast Cancer
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Trials With No Placebo
Behavioral Intervention
Pelvic Floor Physical Therapy + Psychosocial Treatment for Bladder Pain Syndrome
"This trial aims to understand how different subgroups of patients with interstitial cystitis/bladder pain syndrome respond to two common treatments - pelvic floor physical therapy and cognitive-behavioral therapy. The goal
Alkylating agents
Hepatic Arterial Infusion + Chemotherapy for Colorectal Cancer Liver Metastases
This trial is testing a new cancer treatment for people who have had part of their liver removed. It's a combination of two drugs given through an IV, plus a third drug given through a pump that goes directly to the liver. The goal is to find the best dose of each drug to give, based on how well the patient tolerates the treatment.
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitors for Hypereosinophilic Syndrome
This trial is for patients with a rare blood disorder called hypereosinophilic syndrome, who have not responded to standard treatment. The study will test whether the drug imatinib mesylate (Gleevec) is safe and effective in reducing blood eosinophils in these patients.
Corticosteroid
Budesonide for Chronic Obstructive Pulmonary Disease
This trial tests if a triple medication inhaler can improve heart and lung health in high-risk COPD patients better than a dual medication inhaler. Using a single inhaler with three medications has been shown to improve lung function and reduce flare-ups in COPD patients compared to using two medications, but it may increase the risk of pneumonia.
View More Related Trials
Frequently Asked Questions
Introduction to ic
What are the top hospitals conducting ic research?
When it comes to cutting-edge clinical trials in the field of interstitial cystitis (IC), hospitals across the United States are making strides towards understanding and treating this condition. In Houston, MD Anderson Cancer Center leads the way with five ongoing IC trials, demonstrating their commitment to finding innovative solutions for patients. Similarly, Stanford University in Stanford is actively involved in four IC trials, having already recorded one trial back in 2009. This renowned university is dedicated to pushing boundaries and expanding knowledge on IC. Meanwhile, Washington University School of Medicine in Saint Louis has also joined the effort with four active IC trials, showcasing their dedication to exploring new treatment options for affected individuals.
Moving eastward to New york City, Columbia University Medical Center is embarking on three active IC trials as they work tirelessly toward unraveling the complexities of this condition. Simultaneously, Memorial Sloan Kettering Cancer Center stands alongside them with three ongoing clinical investigations focused on IC.
Interstitial cystitis presents unique challenges and impacts countless lives worldwide. However, these top hospitals are determined to break new ground and improve outcomes for those living with this debilitating condition through rigorous research endeavors and collaborative efforts. Together they represent a beacon of hope for individuals suffering from interstitial cystitis while striving relentlessly to uncover better treatments and ultimately provide relief for patients everywhere
Which are the best cities for ic clinical trials?
When it comes to clinical trials for IC (interstitial cystitis), several cities stand out as top destinations for research and innovation. New york City leads the way with 22 active trials, focusing on treatments like Soticlestat, Selpercatinib, and Adapted IPS. Los Angeles follows closely behind with 19 ongoing studies investigating Encorafenib, Selpercatinib, and Cytology Specimen Collection Procedure. Philadelphia and Houston tie at 14 active trials each, exploring various interventions such as Tirzepatide Dose 2 and Tetrodotoxin for injection respectively. Lastly, Atlanta contributes to the field with 13 active trials investigating SEP-363856 and Half Dose Pantoprazole plus matching placebo among others. These cities provide individuals living with IC access to cutting-edge clinical trials that pave the way for improved management of this condition.
Which are the top treatments for ic being explored in clinical trials?
In the realm of clinical trials, there are several top treatments currently being explored for ic. These include:
- Daratumumab: with 6 active trials and a total of 134 breast cancer trials since its introduction in 2012.
- Belantamab mafodotin: showing promise in 4 ongoing trials and having participated in 26 all-time breast cancer studies since its arrival in 2018.
- Lenalidomide: involved in three current research projects focused on breast cancer and an impressive tally of 280 all-time clinical trials since debuting back in 2003.
What are the most recent clinical trials for ic?
Exciting advancements are taking place in the field of interstitial cystitis (IC) research, with several recent clinical trials offering new possibilities for patients. One notable trial is investigating the effectiveness of deucravacitinib, a potential treatment for IC that has entered phase 4. Additionally, rifaximin 550 MG oral tablet (XIFAXAN), currently in phases 2 and 3, shows promise as a therapeutic option. Another study explores the combination of BIIB091 and DRF standard dose to address IC symptoms in phase 2. Furthermore, dose exploration is being conducted as part A of a phase 1 trial for IC treatment options. Finally, GEM-ABR (Gemcitabine - Abraxane) therapy coupled with TheraBionic device usage is being examined in phase 2 trials. These ongoing investigations hold great potential to improve outcomes and quality of life for individuals living with interstitial cystitis.
What ic clinical trials were recently completed?
A recent clinical trial investigating the efficacy of low-dose naltrexone in treating ic has been completed. Sponsored by NorthShore University HealthSystem, this trial concluded in September 2021. The results of this study are anticipated to shed light on potential therapeutic options and help improve the management of ic for patients.